DMAE
DMAE alleviates the behavioral problems and hyperactivity associated with Attention Deficit Disorder (ADD) [DMAE increases Attention Span, decreases Aggression, improves Learning ability and sometimes increases Intelligence in 70% of ADD patients].
DMAE increases Attention Span [after 6 weeks of DMAE supplementation students were able to concentrate at lectures better and were able to study and concentrate on exams better].
DMAE inhibits and reverses the Cross-Linking of proteins. to order $4.95
DMAE extends the lifespan of mice by 27-49%.
DMAE facilitates the removal of Lipofuscin from Neurons.
DMAE decreases the incidence and severity of Hangovers in people who consume excessive amounts of Alcohol [after 6 weeks of DMAE use subjects reported freedom from the depression or headaches associated with hangovers].
DMAE may improve Athletic Performance (by improving the body’s production of Energy) [anecdotal reports: many athletes report increased subjective feelings of Energy following DMAE supplementation].
DMAE increases the body’s production of Energy and persons using DMAE subjectively report increases in their levels of Energy.
DMAE mildly stimulates the Central Nervous System (CNS).
Most people who use DMAE supplements report that after 3-4 weeks of DMAE use, they notice a continual mild stimulation of their CNS without side effects.
DMAE increases Alertness.
DMAE alleviates Anxiety [subjects administered 1,200 mg of DMAE per day for 5 days exhibited better control of anxious reactivity].
DMAE increases Assertiveness [after 6 weeks of DMAE supplementation subjects reported having a more outspoken personality].
DMAE reduces Apathy and increases Motivation in persons afflicted with Depression.
DMAE improves the Interhemispheric Flow of Information in the Corpus Callosum of the Brain (thereby improving Creativity and Verbal Fluency).
DMAE improves the behavior and Mental Function of children afflicted with Down’s Syndrome.
DMAE exerts favorable effects on those chronic Dyskinesias (including Tardive Dyskinesia) that occur as a result of long periods of use of Major Tranquilizers.
DMAE increases Intelligence (especially in children).
DMAE improves Learning and Memory.
DMAE decreases the accumulation of Lipofuscin within the Brain.
DMAE elevates Mood [after 6 weeks of DMAE supplementation, subjects reported more affable moods].
DMAE reduces the amount of Sleep required by about 1 hour per night [this effect noted after 6 weeks of DMAE use].
DMAE causes Dreams to become more lucid (vivid).
DMAE users experience a sounder Sleep [after 6 weeks subjects reported waking earlier and having a clearer mind upon waking].
DMAE increases daytime motivation and physical Energy in persons afflicted with Insomnia.
DMAE increases Willpower [after 6 weeks of DMAE use, subjects who previously were unable to stop smoking reported success].
DMAE removes Lipofuscin (age spots) from the skin.
DMAE increases Acetylcholine levels within the Brain:
Medical researchers have speculated that the means by which DMAE increases Brain Acetylcholine levels is by inhibiting Choline metabolism in peripheral tissues, thereby allowing free Choline to accumulate and subsequently enter the Brain where it is converted to Acetylcholine.
DMAE increases the content of Ribonucleic Acid (RNA) in the Brain [research - rats].
DMAE is a component of the chemical structure of Centrophenoxine.
DMAE increases the concentration of Choline in the bloodstream because it enhances the rate at which free Choline enters the blood from other tissues:
DMAE increases the levels of Choline in the brain due to DMAE’s superior ability to cross the Blood-Brain Barrier.
DMAE inhibits the metabolism of Choline in peripheral tissues (permitting “free” Choline to enter the Brain and stimulate the production of Acetylcholine) [research - mice].
References
· Pfeiffer, C., et al. Stimulant effect of 2-Dimethyl-l-aminoethanol (DMAE): Possible precursor of brain acetylcholine. Science. 126:610-611, 1957.
· Caille, E. J. Study concerning the bisorcate demanol effects upon quantified EEG, cortical vigilance and mood. Comparative double-blind, cross-over balanced design versus pirisudanol. Psychol. Med. 18:2069-2086, 1986.
· Pieralisi, G., et al. Effects of a standardized ginseng extract combined with dimethylaminoethanol bitartrate (DMAE), vitamins, minerals and trace elements on physical performance during exercise. Clin Ther. 13(3):373-382, 1991.
· Coleman, N., et al. DMAE in the treatment of hyperactive children. Psychosomatics. 17:68-72, 1976.
· Knoble, M. 2-Dimethylaminoethanol (DMAE) in behavior problems of children. Science Medicine (Buenos Aries). 119:939-944, 1961.
· Lewis, J. A., et al. DMAE and methylpheni date in minimal brain dysfunction. Clin Pharmacol Ther. 17:534-540, 1975.
· Oettinger, L. The use of DMAE in the treatment of disorders of behavior in children. Journal of Pediatrics. 53:671-675, 1958.
· Murphree, H. B., et al. The stimulant effect of 2-diethylaminoethanol (DMAE) in human volunteer subjects. Clinical Pharmacology and Therapeutics. 1:303-310, 1960.
· Ceder, G., et al. Effects of 2-Dimethylaminoethanol (DMAE) on the metabolism of choline in plasma. Journal of Neurochemistry. 30:1293-1296, 1978.
· Zs-Nagy, I., et al. On the role of cross-linking of cellular proteins in aging. Mech Aging Dev. 14:245-251, 1980.
· Sergio, W. Use of DMAE (2-dimethylaminoethanol) in the induction of lucid dreams. Medical Hypotheses. 26:255-257, 1988.
· Hochschild, R. Effect of dimethylaminoethyl (DMAE) p chlorophenoxyacetate on the life span of male swiss webster albino mice. Exp Geront. 6:133, 1971.
· Pfeiffer, C. C. Parasympathetic neurohumors. Possible precursors and effect on behavior. International Review of Neurobiology. 1959:195-244.
· Rosenberg, G. S., et al. The use of cholinergic precursors in neuropsychiatric diseases. American Journal of Clinical Nutrition. 36:709-720, 1982.
· Lambert, P. A., et al. Dimethylaminoethanol (DMAE) in the treatment of late dyskinesia induced by neuroleptic drugs. Ann Med Psychol. 136:625-629, 1978.
· Stafford, J. R., et al. Deanol acetamidobenzoate (DMAE) in tardive dyskinesia. Diseases of the Nervous System. 38:3-6, 1977.